Make your appointment or second opinion with Dana-Farber today to meet with an onsite specialist.

Adult Patients:877-442-3324

Pediatric Patients:888-733-4662

Make Appointment OnlineInternational Patients

Online second opinions

Can’t get to Boston? Explore our Online Second Opinion service to get expert advice from Dana-Farber oncologists.

Request a second opinion

Contact & Directions

Email Dana-Farber

Main Number617-632-3000

Toll-Free Number866-408-DFCI (3324)

Maps & DirectionsContact InformationSend us a Question or Comment

How to Help

Discover the ways to give and how to get involved to support Dana-Farber.

Learn More
Give now

Dana-Farber receives $900 thousand grant to research ovarian cancer

Ursula Matulonis, MDUrsula Matulonis, MD

Researchers at Dana-Farber Cancer Institute were awarded a $900,000 grant from the Ovarian Cancer Research Fund (OCRF) to test new combinations of targeted drugs against the disease.

Ursula Matulonis, MD, the director of the Gynecological Cancer Treatment Center in the Susan F. Smith Center for Women’s Cancers at Dana-Farber is the principal investigator of the Program Project Development Grant from OCRF. This grant helped mark OCRF’s 20th anniversary for which foundation awarded an unprecedented $6.9 million in research and program grants to support gynecologic cancer patients.

“The ultimate goal of this project is to quickly bring laboratory-tested and verified novel drug combinations into ovarian cancer clinical trials,” says Matulonis.

She notes that treatment advances in ovarian cancer have reached a plateau. “Newer agents that target ovarian cancer genetic abnormalities have shown some efficacy as single agents, but cancer cells eventually figure out ways to grow despite the drug,” says Matulonis.  Because of that, Matulonis and her team will explore a number of strategies that combine drugs that simultaneously target several abnormal biologic pathways in ovarian cancer cells. In one project, researchers will test the effectiveness of a PARP inhibitor and another targeted therapy in blocking the abnormal PI3-kinase signaling pathway in ovarian tumors.

A second project will combine two drugs – a heat shock protein (HSP) inhibitor and a PARP inhibitor – aimed at preventing damaged ovarian cancer cells from repairing themselves. The third project will use a technique called BH3 profiling, which measures how close cancer cells are to destroying themselves, to evaluate targeted drug combinations.

Other investigators funded by the grant are Gerburg Wulf, MD, PhD, of Beth Israel-Deaconess Medical Center; and Dana-Farber researchers Panagiotis Konstantinopoulos, MD, PhD; Anthony Letai, MD, PhD; Joyce Liu, MD, MPH, and William Barry, PhD.


8/23/2017 10:19:20 AM
  •   Email
  •   Print
  •   Share
  • Media Contacts

    • For all inquiries, call 617-632-4090 and ask to speak to a member of the media team. Please direct emails to
  • Make an Appointment

    • For adults:
      877-442-3324 (877-442-DFCI)

    • Quick access:
      Appointments as soon as the next day for new adult patients

    • For children:
      888-733-4662 (888-PEDI-ONC)

    • Make Appointment Online